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Hepatocellular carcinoma is the fifthmost commonsolid cancerworldwide. Sorafenib, a smallmultikinase inhibitor, is the
only approved therapy for advanced HCC. The clinical benefit of sorafenib is offset by the acquisition of sorafenib
resistance. Understanding of the molecular mechanism of STAT3 overexpression in sorafenib resistance is critical if the
clinical benefits of this drug are to be improved. In this study, we explored our hypothesis that loss of RFX-1/SHP-1 and
further increase of p-STAT3 as a result of sorafenib treatment induces sorafenib resistance as a cytoprotective response
effect, thereby, limiting sorafenib sensitivity and efficiency. We found that knockdown of RFX-1 protected HCC cells
against sorafenib-induced cell apoptosis and SHP-1 activity was required for the process. SC-2001, a molecule with
similar structure to obatoclax, synergistically suppressed tumor growthwhen used in combinationwith sorafenib in vitro
andovercamesorafenib resistance throughup-regulatingRFX-1 andSHP-1 resulting in tumor suppression andmediation
of dephosphorylation of STAT3. In addition, sustained sorafenib treatment in HCC led to increased p-STAT3whichwas a
key mediator of sorafenib sensitivity. The combination of SC-2001 and sorafenib strongly inhibited tumor growth in both
wild-type and sorafenib-resistant HCC cell bearing xenograftmodels. These results demonstrate that inactivation of RFX/
SHP-1 induced by sustained sorafenib treatment confers sorafenib resistance to HCC through p-STAT3 up-regulation.
These effects can be overcome by SC-2001 through RFX-1/SHP-1 dependent p-STAT3 suppression. In conclusion, the
use of SC-2001 in combination with sorafenib may constitute a new strategy for HCC therapy.
Neoplasia (2014) 16, 595–605Introduction
Hepatocellular carcinoma (HCC) is a leading cause of death
worldwide [1,2]. Most HCC patents are diagnosed at the late stage
of HCC, when existing therapies are ineffective. Traditional
chemotherapy has a limited effect on HCC patient survival.
Sorafenib, a multikinase inhibitor with a phenylurea structure, is
the first and only targeted drug therapy approved by the FDA for the
treatment of patients with HCC [3]. In HCC, sorafenib targets
several kinases, such as Raf, VEGFR, PDGFR [4–7]. Although
596 SC-2001 overcomes sorafenib resistance through RFX-1 activation Su et al. Neoplasia Vol. 16, No. 7, 2014sorafenib showed survival benefit in a phase III clinical study, it only
prolonged survival from a median of 7.9 to 10.7 months. Apart from
the complex heterogeneity of HCC that may hamper the effect of
sorafenib, acquisition of resistance to sorafenib is an emerging clinical
problem and potentially manageable [8,9]. Therefore, it is important
to elucidate the molecular mechanisms of sorafenib resistance, and
develop new drugs that improve sorafenib response.
STAT3 is associated with chemotherapy failure [10–12], and a
selection of angiogenic, invasive [13] and resistant clones. Because of
unsatisfactory results with DNA alkylating or intercalating drugs,
protein drugs have beenwidely studied inmany cancers.However, their
efficacy is often short-lived, and treatment is often accompanied by
acquired resistance, which may be due to the activation of STAT3
which turns on survival pathways that reverse the therapeutic effect
[14,15]. Our previous studies have indicated that TRAIL induced an
apoptotic effect in HCC cells depending on the level of p-STAT3 [16].
In addition, sorafenib resistant HCC cells (Huh7 SR-1 and SR-2)
exhibited higher levels of expression of p-STAT3 than sensitive cells
[17]. Here, we hypothesized that STAT3 induced by escalation of
sorafenib in HCC cells over a long period of time may restrict the effect
of sorafenib in HCC. If so, targeting STAT3 in sorafenib resistant cells
with a “sensitizer” could conceivably constitute a strategy for the
complete suppression of HCC growth through sorafenib therapy.
SC-2001, a small molecule with a structure similar to obatoclax,
has been shown to block protein-protein interaction between
members of the anti-apoptotic Bcl-2 family and the pro-apoptotic
Bcl-2 family [18]. Our previous studies showed that SC-2001 is able
to enhance SHP-1 expression and further repress STAT3 phosphor-
ylation in HCC cells [19]. SHP-1, a members of the Src homology 2
(SH2)-domain containing tyrosine phosphatase family, is one of the
protein tyrosine phosphatases that can deactivate STAT3 signaling
through direct dephosphorylation of p-STAT3 (Tyr 705) [20–22]. In
addition, SHP-1 is a negative regulator of several signaling pathways
involved in cancers [23,24], and it can be regulated by several
transcription factors [25,26]. RFX-1 is a transcription factor that has
been reported to positively modulate SHP-1 expression in breast
cancer [27]. However, the regulation of SHP-1 in HCC is far from
clear. In this study we used HCC cells and xenograft models to
explore whether up-regulation of STAT3 induced by sorafenib
treatment over a long period of time could lead to sorafenib resistance,
and tested whether SC-2001 could overcome such resistance by
activation of RFX-1/SHP-1 and repression of STAT3.
Materials and Methods
Synthesis, Purification, and Characterization of SC-2001
SC-2001 ((Z)-2-((3-methoxy-2H-pyrrol-2-ylidene)methyl)-1H-
pyrrole) compounds were synthesized and purified in the medicinal
chemistry laboratory at the Institute of Biopharmaceutical Sciences,
National Yang-MingUniversity, Taiwan. The detailed synthetic process
has been described in our previous study. SC-2001 compounds were
subjected to nuclear magnetic resonance and mass spectrometry for
structure and molecular weight characterization. The molecular weight
of SC-2001 calculated by high-resolution mass spectrometry for
C18H14BrN3O (M+H
+) was 368.0393.
Cell Culture and Antibodies
The Huh7 HCC cell line was obtained from the Health Science
Research Resources Bank (HSRRB; Osaka, Japan; JCRB0403).The PLC/PRF/5 (PLC5) cell lines were obtained from American
Type Culture Collection (ATCC). All cells obtained from HSRRB or
ATCC were immediately expanded and frozen down such that all cell
lines could be restarted every 3 months from a frozen vial of the same
batch of cells. No further authentication was conducted in our
laboratory. Cells were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% FBS, 100 units/mL
penicillin G, 100 mg/mL streptomycin sulfate, and 25 mg/mL
amphotericin B in a humidified incubator at 37 °C in an atmosphere
of 5% CO2 in air. Results from all in vitro studies were confirmed in
at least three independent experiments to verify results. Antibodies
for immunoblotting such as p-STAT3(Tyr705), STAT3, survivin,
caspase-3 and caspase-9 were from Cell Signaling (Danvers, MA).
SHP-1, cyclin D1 and Mcl-1 antibodies were purchased form Abcam
(Cambrige, MA). RFX-1 antibody was purchased from Novus
Biologicals (Colorado, USA).
Development of Sorafenib Resistant Huh7 Cells
The human HCC cell line Huh7 was exposed to sorafenib from
low dose (2.5 μM) and when cells stably grew then started to change
to the higher dosage of sorafenib (5, 7.5, and then 10 μM). Medium
containing sorafenib was replaced every two days for three months.
In the ends, the cells could grow slowly in medium containing 10 μM
sorafenib (a clinically relevant dose). The sorafenib resistant cells
(Huh7 R1 and Huh7 R3) were routinely maintained under constant
culture condition containing sorafenib.
Apoptosis Analysis
The following twomethods were used to assess drug induced apoptotic
cell death: measurement of apoptotic cells by cell death detection ELISA
for cytoplasmic histone-associatedDNA fragments (Roche), andWestern
blot analysis for caspase-3 and -9 cleavage. Release of oligonucleosomes
into the cytoplasm was quantified by cell death ELISA.
Preparation of Nuclear Extracts and Cytosolic Extracts
Nuclear extracts were prepared using NE-PER nuclear and
cytoplasmic extraction reagent according to the manufacturer’s
instructions (Pierce Biotechnology). Briefly, 1 × 106 cells were
trypsinized, followed by lysing in 200 mL CERI buffer. After the
lysates were vortexed for 15 s and incubated on ice for 10 min, 11 mL
of CERII was added. The lysates were vortexed for 5 s, incubated on
ice for 1 min, and vortexed again for 5 s. The nuclei were pelleted at
16,000 g at 4 °C for 5 min, and the cytoplasmic extracts were
removed and collected. Nuclei were resuspended in 25 ml nuclei
extraction buffer and vortexed 15 s. The nuclei were extracted on ice
and vortexed for 15 s every 10 min, for a total of 40 min. The extracts
were centrifuged at 16,000g at 4 °C for 5 min and the supernatant was
collected as nuclear extract. Protein concentration was determined by
BCA Protein Assay using BSA as a standard (Pierce Biotechnology).
Chromatin Immunoprecipitation (CHIP) Assay
CHIP assay was performed according to the protocol provided
with the EZ ChIP chromatin immunoprecipitation and EZ-Zyme
Chromatin prep kit (Upstate Biotechnology, Lake Placid, NY).
Briefly, after cross-linking with 17.5% paraformaldehyde, PLC5 cells
were washed with phosphate-buffered saline and lysed in lysis buffer. The
DNA was fragmented to about 200–500 base pairs by the EZ-Zyme.
Approximately 5 × 106 cells were used per CHIP assay and the resulting
DNA fragments were incubated with 2 μg RFX1 antibodies, which were
Figure 1. RFX-1 contributes to the growth inhibition effect of sorafenib inHCCcells. (A) Left, The cell proliferation of PLC5sh-Vector (sh-vector
clone1 and 2) and sh-RFX-1 (sh-RFX-1 clone1 and 2) cellswere analyzedbyMTT assay under sorafenib treatment. *Pb 0.05, **Pb 0.01.Right,
The protein levels of RFX-1, SHP-1, and p-STAT3 in PLC5 sh-Vector (sh-vector clone 1 and 2) and sh-RFX-1 (sh-RFX-1 clone 1 and 2) cells were
determinedbywestern blot. Actinwasusedasa loadingcontrol. (B) Left, Theprotein levelsofRFX-1, SHP-1, andp-STAT3 inHuh7WT,R1, and
R3 cells were determined bywestern blot. Actinwas used as a loading control.Middle, The levels of nuclear extraction of RFX-1 in Huh7WT,
R1, and R3 cells weremeasured bywestern blot. Right, Chromatin immunoprecipitation assay was performed in Huh7WT, R1, and R3 cells.
The crude lysates fromWT, R1, and R3 cellswere immunoprecipitated, respectively,with RFX-1 antibody and rabbit IgG control and captured
by protein A-agarose beads. The precipitated DNA fragments were amplified by PCR to detect fragments in SHP-1 promoter containing the
RFX-1 binding site.
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immunoprecipitated products were washed sequentially with low-salt
immune complex wash buffer, high-salt immune complex wash buffer,
LiCl immune complex wash buffer, and twice with TE buffer. The
chromatin was eluted from the agarose by incubating with elution buffer
(1% SDS, 100mM NaHCO3); and the DNA–protein complexes were
reversely cross-linked by high-salt solution containing 200 mMNaCl at
65 °C for at least 5 h. To eliminate contamination of proteins andRNAs,
the mixture was treated with 10 mg RNase A at 37 °C for 30 min and
then treated with protease K for 2 h at 45 °C. Finally, the precipitated
DNAwas recovered using the spin column provided in theChIP kit, and
eluted with 50ml elution buffer. PCR reaction was conducted usingTaq
DNA polymerase (MyTaq). Two microliters of the precipitated DNA
was used as template. The sequences of the primers used in the ChIP
assay were as follows: 5′-CCTCTTGCAGGTGTCCTTAAG-3′,and
5′-TGGAAAGGCAGAGGGAATCAG-3′.
Dual Luciferase Assay
After transfection with firefly luciferase reporter construct and
reference pCMV-renilla luciferase plasmid for 48 h, cells were
collected and lysed with passive lysis buffer. The lysate was placed into
glass tube and promoter activity was analyzed by dual luciferase assay
according to the instruction manual.Gene Knockdown using siRNA
Smart-pool small interfering RNAs (siRNAs), including the
control (D-001810-10), SHP-1, and RFX-1, were purchased from
Dharmacon (Chicago, IL). The knockdown procedure was as
described previously [21]. Briefly, Huh7 R1 and R3 cells were
transfected with siRNAs against the phosphatases given above or
the control sequence for 48 hours and then treated with SC-2001 at
the indicated concentrations. The cell extracts were analyzed by
western blot.
Generation of PLC5 cells with Stable Knockdown of RFX-1
The RFX-1 silencing stable cell line, PLC5-shRFX-1, was obtained
by transfection of HuSH-shRNA-GFP cloning vector (pGFP-V-RS)
or HuSH-shRFX-1-GFP cloning vector (pGFP-V-RS-shRFX-1) into
PLC5 cells using Dharmafect 4 transfection reagent (Thermo
Scientific). Two days post-transfection, the PLC5-sh-control (sh-vector
clone 1 and 2) and the PLC5-sh-RFX-1 (sh-RFX-1 clone 1:
TGCGGCTGATGGAGGACCAGCAGCACATG and sh-RFX-1
clone 2: CCTCAAGTGGTCCTTCTACAGCTCCATGG) cells were
selected and placed in medium containing 1.5 μg/ml puromycin for
2 weeks. Cells were routinely maintained under constant
culture conditions. Control and shRNA plasmids were purchased
from Origene.
Figure 2. SC-2001 overcomes sorafenib resistance in HCC cells by enhancing cell viability, inhibition and apoptosis. (A) Top, DNA
fragmentation assay was performed in Huh7 WT, R1, and R3 cells undergoing sorafenib treatment at different dosages. Bottom, DNA
fragmentation assaywas performed inHuh7R1 andHuh7R3 cells undergoing SC-2001 treatment at different dosages. (B) Huh7R1 (left) and
Huh7R3 (right) cellswere treated, respectively,with sorafenib andSC-2001 in dosedependentmanner for 48h.Cell viabilitywasmeasuredby
MTT assay. **P b 0.01. (C) Huh7 R1 (left) and Huh7 R3 (right) cells were treated, respectively, with sorafenib and SC-2001 in dose dependent
manner for 48 h. After treatment, the cells were seeded onto 6-well plates for colony formation assay. After 2 weeks, the cells were stained
with crystal violet and the colonieswere counted. **P b 0.01. (D) The protein levels of caspase-3 and caspase-9 were determined bywestern
blot after Huh7 R1 and Huh7 R3 cells were exposed to sorafenib and SC-2001 for 48 h. Actin was used as a loading control.
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Huh7 R1 and R3 cells were seeded in a 96-well plate and co-transfected
with reference pCMV-renilla luciferase plasmid with a plasmid driven by the
promoter region containing STAT3-specific binding sites. After incubation
for 48 h, the cells were treated with SC-2001 for 6 h and lysed with passive
buffer. The lysates were transferred to a glass tube and promoter activity was
determined by dual luciferase assay according to the manufacturer’s
instructions. The STAT3 Reporter Kit was purchased from SABiosciences.
Determination of Synergism
Drug synergismwas determined using the Chou and Talalaymethod
[28] and the software package CompuSyn (Biosoft). A combination
index (CI) value of less than 1 was defined as synergism [17].SHP-1 Phosphatase Activity
A RediPlate 96 EnzChek Tyrosine Phosphatase Assay Kit (R-22067)
was used for the SHP-1 activity assay (Molecular Probes, Carlsbad, CA).
The method was as described previously [16].
Colony Formation Assay
Huh7 R1 and R3 cells were seeded in 6-well plates (~1000-5000
cells per well) and subjected to the indicated treatments, with the drug
being removed to terminate the treatment. Two weeks later, plates
were washed in PBS, fixed with 100% methanol and stained with a
filtered solution of crystal violet (5% w/v). After washing with tap
water, the colonies were counted both manually and digitally using a
ColCount TM plate reader (Oxford Optronics, Oxford, England).
Figure 3. Induction of RFX-1/SHP-1 by SC-2001 plays a role in overcoming STAT3 dependent-sorafenib-resistance in HCC cells. (A) Huh7
R1 and R3 cells were exposed to SC-2001 in dose dependent manner for 24 h. The cell lysates were subjected to western blot analysis
with p-STAT3, Mcl-1, survivin, and cyclin D1 antibodies to analyze protein levels. Actin was used as a loading control. (B) Left, STAT3
activity ELISA was performed in Huh7 R1 and R3 cells after treatment with SC-2001 in dose dependent manner for 24 h. Right, Huh7 R1
and R3 cells were transfected with either vector or luciferase reporter driven by a promoter region containing STAT3-specific binding sites
for 48 h. After transfection, the cells were treated with SC-2001 in dose dependent manner for 6 h. Luciferase activity was measured after
the treatment. (C) The mRNA levels of SHP-1 and the protein levels of SHP-1 and RFX-1 in Huh7 R1 and R3 cells were determined.
The mRNA level was analyzed by QPCR and the protein level was analyzed by western blot. (D) Top, Huh7 R1 and R3 cells were treated
with SC-2001 in dose dependent manner. After treatment, the nuclear and cytosol extraction of RFX-1 was measured by western blot.
Histone H1 was included as a loading control NE. Bottom, immunofluorescence staining, Huh7 R1 and R3 cells cells were treated with
4 μM SC-2001 for 24 h. After the end of treatment, RFX-1 was determined by immunofluorescence staining (red). Nuclei were
counterstained with DAPI (blue). Representative confocal micrographs are shown. (E) Chromatin immunoprecipitation assay (CHIP) was
conducted in Huh7 R1 and R3 cells after exposure to SC-2001 for 12 h. CHIP assay was performed as described above.
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Huh7 R1 and R3 cells were seeded at a density of 2 × 105 cells/well
on glass coverslips in 6-well plates two days prior to experimental
manipulation. For immunofluorescence staining of RFX-1, cells
grown on coverslips were washed twice with cold PBS, fixed with ice-
cold methanol for 10min at -20 °C, and permeabilized with 0.5% (v/v)
Triton X-100 in PBS for 5 min at room temperature, followed by
incubation with blocking solution for 1 h at room temperature.
Coverslips were incubated with primary antibodies against human
RFX-1 (Novus Biologicals) for 1 h at 37 °C, washed with PBST (0.2%
Tween 20 in PBS), and subsequently incubated with rabbit secondary
antibody conjugated with rhodamine for 30 min at room temperature.
Afterwards, the coverslips were washed and mounted with fluorescent
mounting medium (Dako). Fluorescence images will be taken with
Zeiss LSM 510 confocal microscope scanning.Real-time PCR (QPCR)
Total RNA was isolated from cell lines with TRIzol (Invitrogen)
and cDNA was prepared from 2 mg of RNA using a First-Strand
cDNA Synthesis Kit according to the manufacturer’s instructions
(Amersham Biosciences, Amersham, UK). Oligonucleotide sequences
were as follows: SHP-1, 5′-GCC CAG TTC ATT GAA ACC AC- 3′
(sense) and 5′-GAGGGAACCCTTGCTCTTCT-3′ (antisense);
GAPDH, 5′-CGACCACTTTGTCAAGCTCA-3′(sense) and 5′-
AGGGGTCTACATGGCAAC TG-3′ (antisense); RFX-1: 5′-
CGGCAAGCACCAGCTACTAC-3′ (sense) and 5′-GGACACG
TACATGGGCATGG-3′ (antisense). For QPCR, thermocycling
was performed in a final volume of 20 μl containing 2.5 μl of cDNA
sample, 200 nM of each of the primers, and 6.5 μl of SYBR Green I
Master Mix (Roche) with Roche LightCycler 480 sequence detection
system (RocheApplued Science, Foster, California). The following
Figure 4. SC-2001-induced inhibitionof colony formation in sorafenib-resistantHCCcells is RFX-1/SHP-1 dependent. (A) Huh7R1andR3cells
were transfected, respectively, with control siRNA or SHP-1 siRNA for 48 h. After transfection, the cells were treatedwith orwithout SC-2001
for 24 h and subjected to western blot assay to analyze the protein levels of p-STAT3 and SHP-1 or seeded on a 6-well plate for the colony
forming assay. (B) Huh7 R1 and R3 cells were transfected, respectively, with control siRNA or RFX-1 siRNA for 48 h. After transfection, the
cells were treated with or without SC-2001 for 24 h and subjected to western blot assay to analyze the protein levels of RFX-1 and SHP-1 or
seeded on a 6-well plate for the colony forming assay. (C) Huh7 R1 and R3 cells were transfected, respectively, with control vector or RFX-1
overexpression plasmid for 48 h. After transfection, the cells were treated with or without SC-2001 for 24 h and the cells were subjected to
western blot assay to analyze the protein levels of RFX-1 and SHP-1 or seeded on a 6-well plate for colony forming assay.
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by 35 cycles of 94 °C for 1 min, annealing for 1 min at 57 °C, and
elongation for 1 min at 72 °C, and a final elongation step at 72 °C for 10
min. Expression levels of genes of interest were normalized to that of
GAPDH in the same sample.
Xenograft Tumor Growth
Male NCr athymic nude mice (5-7 weeks of age) were obtained from
the National Laboratory Animal Center (Taipei, Taiwan). When Huh7
andHuh7-resistant tumors (Huh7 R3) reached 100mm3, mice received
sorafenib (10 mg/kg) and/or SC-2001 (10 mg/kg) orally (every other
day). Controls received vehicle.
Clinical Specimens
The liver tissues from 11 HBV and HCV negative male
HCC patients collected in the Taiwan Liver Cancer Network
(TLCN) were included in this study. The HCC samples were
used for examining the relationship between RFX-1 and SHP-1
mRNA expression clinically. The Institutional Review Board
of National Yang-Ming University approved the use of these
archived tissues.
Statistical Analysis
Data are expressed as mean ± SD or SE. Statistical comparisons
were based on nonparametric tests and statistical significance wasdefined as P b 0.05. All statistical analyses were performed using SPSS
for Windows version 12.0 software (SPSS, Chicago, IL).
Results
RFX-1 Contributes to the Growth Inhibition Effect of
Sorafenib in HCC Cells
To figure out the importance between RFX-1 and sorafenib in
HCC cells, we first tested its growth effect in PLC-5 cells. In
agreement with previous reports [21,29], sorafenib showed high levels
of growth inhibition at 10 μM. Next, to test our hypothesis that
RFX-1 plays a role in cell proliferation, we knocked down RFX-1 in
PLC-5 cells and explored the drug effect of sorafenib at various doses.
By the sh-RNA technique, we generated two RFX-1 knockdown-
PLC5 clones by transfecting two different sh-RFX-1 plasmids. As
shown in Figure 1A, left, treatment of RFX-1 knockdown-PLC-5
cells (both in sh-RFX-1 clone 1 and 2) with sorafenib at 10 μM
significantly decreased growth inhibition in comparison with vector
control PLC-5 (sh-vector clone 1 and 2), indicating that RFX-1
might be involved in the activity of sorafenib. The protein expressions
of RFX-1, SHP-1, and p-STAT3 in two RFX-1 knockdown-PLC5
cells were confirmed by western blot. The protein expressions of
RFX-1 and SHP-1 were decreased in two RFX-1-silencing PLC5
clones compared to the vector control cells. In addition, p-STAT3
expression was increased after RFX-1 was knockdown in PLC5 cells
Figure 5. Use of SC-2001 in combination with sorafenib synergizes the anticancer effect. (A) Huh7 R1 and R3 cells were treated with a
range of concentrations sorafenib and/or SC-2001 at a fixed ratio of 5:1 for 48 h. The colony formation (top) and western blot (bottom)
were performed as described above after the treatment. (B) Top, Huh7 R1 and R3 cells were treated as described above and the STAT3
activity ELISA was performed after the treatment. Bottom, Huh7 R1 and R3 cells were transfected with either vector or luciferase reporter
driven by a promoter region containing STAT3-specific binding sites for 48 h. After transfection, the cells were treated as described above
and the luciferase activity was measured after the treatment. (C) The DNA fragmentation and protein levels of caspase-3 and caspase-9
were analyzed in Huh7 R1 and R3 cells after treatment with sorafenib and/or SC-2001 for 48 h as described above. (D) Huh7 R1 and R3
cells were treated with sorafenib and/or SC-2001 for 48 h administered over a range of concentrations at a fixed ratio of 5:1. After the cell
viability was determined in each condition by MTT assay, the combination index (CI) was calculated by CompuSyn software. CI values of
less than 1 were considered to respresent synergism.
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resistant Huh7 cell lines (Huh7 R1 and R3) by treatment with
sorafenib at 2.5 μM escalating to 10 μM over a long period of time. As
shown in Figure 1B, left, both Huh7 R1 and R3 cells had lower
expressions of RFX-1 and SHP-1 compare to wild-type cells, whereas
p-STAT3 showed a reverse effect in these two cell lines. Here, we did
not find obviously difference in STAT5 phosphorylation which is
another STAT family protein (Supplementary Figure 1). This result
suggested that RFX-1 and SHP-1 are two key factors regulating the
contribution of STAT3 to sorafenib-resistance in HCC cells. In
addition, to further determine the regulatory role of RFX-1 in SHP-1
modulation in sorafenib-resistance HCC cells, we next isolated the
nuclear protein extracts of wild type Huh7, Huh7 R1, and Huh7 R3cells. As shown in Figure 1B, middle, Huh7 R1 and Huh7 R3 cells
displayed lower expressions of nuclear RFX-1 compared to wild type
Huh7 cells, furthermore, based on our chromatin immunoprecipitation
(CHIP) results, decreased RFX-1 binding to the SHP-1 promoter was
observed in Huh7 R1 and Huh7 R3 cells (Figure 1B, right). These
results implied that SHP-1 is transcriptionally mediated by RFX-1 in
sorafenib-resistance HCC cells, and decreased RFX-1 expression is
associated with increased resistance of HCC cells to sorafenib.
SC-2001 Overcomes Sorafenib Resistance in HCC Cells by
Enhancing cell Viability, Inhibition and Apoptosis
To gain a better understanding of the effect of SC-2001 on
sorafenib-resistant cells, we determined the cell viability and apoptotic
602 SC-2001 overcomes sorafenib resistance through RFX-1 activation Su et al. Neoplasia Vol. 16, No. 7, 2014effect of SC-2001 treatment in Huh7 R1 and R3 cells. As shown in
Figure 2A, top, sorafenib did not induce DNA fragmentation in
Huh7 R1 and R3 cells. As our previous result showed that SC-2001inhibited p-STAT3 in HCC cells through activating SHP-1
expression, we next explored the effect of SC-2001 in sorafenib
resistant cells. As shown in Figure 2A, bottom, SC-2001 obviously
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Furthermore, as shown in Figure 2B, SC-2001 attenuated cell growth in
Huh7 R1 and Huh7 R3 cells in a dose dependent manner starting at
dosages of 1.25μM. In addition, SC-2001 showed significant inhibition
in these two sorafenib-resistant cell lines asmeasured by colongenic assay
(Figure 2C). Notably, by analyzing the protein expression of caspase-3
and caspase-9, we proved that SC-2001 can induce higher expressions of
cleaved caspase-3 and caspase-9, indicating that SC-2001 obviously led
to more apoptosis than sorafenib in resistant cells (Figure 2D). These
results suggested that SC-2001 has potent effect on sorafenib-resistance
HCC cells.
Induction of RFX-1/SHP-1 by SC-2001 Pa role in Overcoming
STAT3 Dependent Sorafenib Resistance in HCC Cells
Next, to investigate the effect of SC-2001 on the activity of p-STAT3 in
sorafenib-resistant cells, we examined p-STAT3 and its downstream
signalingmolecules such asMcl-1, survivin, and cyclinD1, upon SC-2001
treatment. As shown in Figure 3A, SC-2001 treatment resulted in down-
regulation of p-STAT3 and its targets in a dose-escalation manner in
sorafenib-resistant cells. Next, we applied an ELISA to confirm the effect of
SC-2001 on p-STAT3. As shown in Figure 3B, left, SC-2001 suppressed
STAT3 activity starting at doses of 1 μM. To examine whether SC-2001
could decrease the transcriptional activity of STAT3, a reporter assay was
conducted. The result showed that SC-2001 inhibited the transcriptional
activity of STAT3 in a dose dependentmanner (Figure 3B, right). The level
of SHP-1 was also investigated in order to elucidate the mechanism by
which SC-2001 regulates STAT3. SC-2001 treatment caused a dose-
dependent increase of SHP-1 both at the protein and mRNA levels
(Figure 3C), indicating that SC-2001-regulated SHP-1 expression at the
transcription level in sorafenib resistant cells. In addition, one of the
transcription factors of SHP-1, RFX-1, was correlated with SHP-1
expression upon SC-2001 treatment. Therefore, we investigated whether
SC-2001 enhanced RXF-1 translocation from the cytosol to the nuclei to
activate SHP-1.The results showed thatRFX-1 in the presence of SC-2001
was imported into the nuclei. In addition, based on the results of
immunofluorescence, we also demonstrated that SC-2001 could
enhance the nuclear translocation of RFX-1 (Figure 3D). Moreover,
the CHIP assay results revealed that RFX-1 bound to SHP-1 promoter
under SC-2001 in a dose dependent manner (Figure 3E). These results
showed that SC-2001 treatment changed the nuclear localization of
RFX-1 whose nuclear accumulation is involved in SHP-1 transcription
activity leading to the reduction of STAT3 and restoring sensitivity in
sorafenib-resistant cells.
SC-2001-induced Inhibition of Colony Formation in
Sorafenib-Resistant HCC Cells is RFX-1/SHP-1 Dependent
To further investigate the mechanism through which SC-2001
increased RFX-1/SHP-1 and decreased p-STAT3 in sorafenib-resistant
cells, we knocked down SHP-1 with siRNA to address whether SHP-1Figure 6. SC-2001 potentiates the antitumor effect of sorafenib in both
(A) Left, Huh7-resistant cells were subcutaneously injected into nude mi
sorafenib and/or SC-2001 orally for 2 weeks. Tumor volume was meas
andMethods.Right, The bodyweight of nudemice bearingHuh7-resista
p-STAT3 in Huh7-resistant cells in vivo were determined by western
determined. (C) Left, Huh7-wild type cells were subcutaneously injecte
treatedwith sorafenib and/or SC-2001orally for 2weeks. The tumor volum
Materials and Methods. Right, The body weight of nude mice bearing H
of RFX-1, SHP-1, and p-STAT3 in Huh7wild-type cells were determined b
was determined.is associated with sorfenib resistance. As shown in Figure 4A, SC-2001
treatment increased SHP-1 and repressed p-STAT3. However, SHP-1
silence abolished the effects of SC-2001 on p-STAT3 in sorafenib-
resistant cells, indicating the critical role of SHP-1 in SC-2001-induced
inhibition of cell growth. Importantly, silencing RFX-1 resulted in
inhibition of SHP-1 activity and further restored cell growth upon SC-
2001 treatment (Figure 4B). On the other hand, genetic overexpression
of RFX-1 potentiated the effect of SC-2001 in activating SHP-1 which
led to significant growth inhibition in sorafenib-resistant cells. These
results proved that RFX-1 and SHP-1 silencing could prevent SC-2001-
mediated STAT3 reduction (Figure 4C). We therefore concluded that
SC-2001 overcome sorafenib resistance in HCC cells by activating
RFX-1 expression.
Use of SC-2001 in Combination with Sorafenib
Synergizes the Antitumor Effect
Both Huh7 R1 and R3 cells had lower expression of RFX-1 and
SHP-1 than Huh7 wild type. Also, these two cell lines were resistant
to sorafenib at 10 μM due to the high expression level of STAT3.
As SC-2001 activated RFX-1 in HCC cells as described above, we next
investigated the effect of SC-2001 and sorafenib combination treatment
in sorafenib resistant cells. As shown in Figure 5A, combination
treatment resulted in significant down-regulation of p-STAT3 and its
downstream signals in both sorafenib-resistant cell lines. In addition,
the colony forming ability of sorafenib-resistant cells was markedly
decreased by the combination treatment. Moreover, we examined the
STAT3 activity in target gene regulation through ELISA and luciferase
assays. The results indicated that the combination of sorafenib and SC-
2001 synergistically suppressed STAT3 activity (Figure 5B). In
addition, the combination also induced more significant caspase-3
and caspase-9 activation than a single agent treatment and led to high
levels of DNA fragmentation (Figure 5C). We also conducted median
effect analysis that showed that the combination index values were lower
than one, indicating that these two agents worked in synergy to induce
cell growth inhibition (Figure 5D).
SC-2001 Potentiates the Antitumor Effect of Sorafenib
in both Sorafenib-Sensitive and Sorafenib-Resistant
Huh7 Xenograft Models
Results of the biological assays demonstrated that p-STAT3 status
and cell survival of wild-type HCC cells was hindered by sorafenib or
SC-2001. SC-2001 and sorafenib in combination inhibited p-STAT3
and cell survival more significantly than either monotherapy in both
in wild-type as well as sorafenib-resistant cells. To examine the
therapeutic effect, wild-type Huh7 and sorafenib-resistant Huh 7 cells
were injected into nude mice to initiate tumor growth and sorafenib
or SC-2001 or combination treatement was administered. Although
wild-type Huh7 tumors treated with sorafenib were smaller than
control for the first 5 days treatment, we observed that sorafenib-sorafenib-sensitive and sorafenib-resistant Huh7 xenograft models.
ce. When tumors reached 100 mm3, themice were then treated with
ured and calculated according to the formula described in Materials
nt cellswasmeasured. (B) Left, The protein levels of RFX-1, SHP-1, and
blot. Right, The in vivo SHP-1 activity in Huh7-resistant cells was
d into nude mice. When tumors reached 100 mm3, the mice were
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uh7-wild type cells was measured. (D) Left, The in vivo protein levels
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treatment and eventually showed moderate growth inhibition at the
end of the treatment, indicating that wild-type Huh7 tumor became
resistant to sorafenib (Figure 6A, left). On the other hand, sorafenib
alone showed no inhibitory effect on sorafenib-resistant bearing
xenograft mice, suggesting that acquired Huh7 resistance reflected
clinical results with sorafenib treatment (Figure 6A, left). Next, we
administrated SC-2001 to both wild-type and sorafenib-resistant
xenograft animals. Treatment with SC-2001 inhibited wild-type Huh7
and sorafenib-resistant growth more significantly than sorafenib
(Figure 6A, left, c, left). Notably, the size of sorafinib-resistant tumors
treated with SC-2001 was only 20% that of vehicle-treated mice at the
end of treatment (Figure 6A, left). More importantly, SC-2001 and
sorafenib combination treatment almost completely repressed tumor
growth in both wild-type and sorafenib-resistant tumors (Figure 6A,
left, C, left). There was moderate weight loss in controls, mono-treated
and combination-treated mice (Figure 6A, right, C, right). In addition,
tumors from control and sorafenib treated-mice did not exhibit RFX-1
and SHP-1 activation signals (Figure 6B, left, D, left). However,
SC-2001 alone or in combination with sorafenib showed an obvious
increase in RFX-1 and SHP-1 expression in both wild-type and
sorafenib-resistant tumors (Figure 6B, left, D, left). The high levels of
expression of RFX-1 and SHP-1 induced by SC-2001 drove SHP-1
activation and further repressed p-STAT3 (Figure 6B andD). Together,
these data demonstrated that SC-2001 overcame sorafenib resistance
through RFX-1 and SHP-1 dependent STAT3 inactivation.
Discussion
This study first demonstrated that RFX-1/SHP-1 activity is lost after
sustained sorafenib treatment in both human HCC cells and a mouse
model. To better understand the mechanisms surrounding sorafenib
resistance, HCC cell lines were treated with SC-2001 and sorafenib,
and tumor resistance, and STAT3 and its target gene levels were
investigated. The results indicated that RFX-1/SHP-1 mediates
sensitivity to sorafenib in HCC cells and sustained sorafenib treatment
resulted in decreased RFX-1/SHP-1, and increased p-STAT3 protein
levels and transcriptional activity. Importantly, the lack of growth
inhibition in resistant HCC in a xenograft model treated with sorafenib
accompanied with decreased RFX-1 suggests that RFX-1 level might be
mediator of HCC response to sorafenib. Since sorafenib is the first and
only targeted therapy drug approved for HCC, we further wanted to
link the correlation between sorafenib resistance and disease diagnosis.
Due to the limitation of human patient samples, no further patients on
the correlation with drug resistance and disease diagnosis could be
made. However, we analyzed the correlation between RFX-1 and SHP-1
in HCC patients (not necessarily receiving sorafenib therapy).
There was a positive relationship between the RFX1 and SHP-1
mRNA levels in 11 HCC patient tissues (stage 1 or 2) with a R2 at
0.5016 (Supplementary Figure 3).
In vitro studies suggested that loss of RFX-1 is able to induce
sorafenib resistance by decreasing sorafenib-induced growth inhibi-
tion. In addition, sustained sorafenib treatment in HCC cells also
resulted in decreased expression and function of RFX-1 targets,
such as SHP-1. SHP-1 is a key contributor to negative regulation of
p-STAT3 [21,29,30] which has been linked to sorafenib-induced
drug resistance [17]. Sustained high levels of expression of p-STAT3
in HCC cells is known to drive the expression of its antiapoptotic
target genes such as Mcl-1, survivin and cyclin D1 [17]. All these
data strongly suggest that RFX-1/SHP-1 might play roles as tumorsuppressors and contribute to a STAT3 dependent sorafenib-
resistance in cells. In addition, the effect of sorafenib-induced
high levels of STAT3 expression in tumors suggests that its use in
combination with a RFX-1 activator may be a rational therapeutic
strategy for HCC treatment.
In light of the fact that SC-2001 could activate RFX-1/SHP-1 and
reduce the level of p-STAT3, we hypothesized that SC-2001 may
overcome STAT3-dependent sorafenib-resistance in HCC cells.
This hypothesis was supported in two sorafenib-resistant HCC cell
lines by cell viability, colony formation and apoptosis results, which
showed that SC-2001 was more effective at inhibiting cell growth and
inducing apoptosis than sorafenib. On the other hand, the protein
level of RFX-1was increased and this gave us a clue that SC-2001
might regulate RFX-1 through transcriptional regulation. As shown
in Supplementary Figure 2, the mRNA of RFX-1 increased
under SC-2001 treatment but not obatoclax, the lead compound of
SC-2001. We also found that SC-2001 used in combination with
sorafenib displayed synergistic tumor growth inhibition both in wild-
type and sorafenib-resistant HCC-bearing xenograft mouse models.
Importantly, in this study low dosages of SC-2001 were able to down-
regulate p-STAT3 through activating RFX-1/SHP-1 in sorafenib
resistant Huh7. The dramatic inhibition tumor growth exerted by
the combination treatment may possibly be explained by the fact that
SC-2001 also acts as an inhibitor of the anti-apoptitic Bcl-2 family
[18]. Indeed, our previous data indicated that SC-2001 significantly
prevented the interaction between Mcl-1 and Bak in HCC cells [19].
Moreover, our data showed that SC-2001 alone also significantly
enhanced the expression of RFX-1/SHP-1 in wild-type Huh-7
xenograft tumors (Figure 6D), supporting that RFX-1/SHP-1/stat3
pathway is also an effector target of SC-2001 in wild-type cells. In
addition to the fact that sorafenib is a well-known multiple kinase
inhibitor that inhibits Raf-1 and other angiogenic kinases (such as
VEGFR2, VEGFR3, Flt-3, PDGFR, and FGFR-1) [7], sorafenib also
can directly interact with SHP-1 to enhance SHP-1 activity, without
affecting SHP-1 expression, and induce apoptosis in HCC cells
(including wild-type Huh7) [21,29,31]. Therefore, it can be
speculated that combination of sorafenib with SC-2001 may also
have synergistic antitumor effect in wild type Huh-7 xenograft tumor, as
supported by our results. It is noteworthy that the level of RFX-1/SHP-1
in the combination treated group was higher than that in SC-2001
alone-treated group, both in sorafenib-resistant Huh7 xenograft
tumors (Figure 6B) and in wild-type Huh7 tumors (Figure 6D).
Furthermore, sorafenib treatment alone did not significant alter
expression of RFX-1/SHP-1 in wild-type Huh7 xenograft tumors.
To our acknowledgement, there is no study reporting sorafenib
could affect the expression of RFX-1/SHP-1. Despite that other off-
targets (other than RFX-1/SHP-1/STAT3 pathway) may also be
involved in the combination effects of sorafenib and SC-2001, the
exact mechanisms to explain why sorafenib could significantly
potentiate the effect of SC-2001 on RFX-1/SHP-1 expression
in these in vivo xenograft tumors remain unclear and future studies
are needed.
Current study has some limitation. Although the sorafenib-resistant
Huh-7 R1 and Huh-7 R3 cells displayed decreased RFX-1 and SHP-1
and increased p-STAT3 which implied a possible mechanism of acquired
sorafenib resistance (Figure 1B), Considering multiple mechanisms of
sorafenib resistance [8], a resistant clone that displayed a similar expression
of RFX-1/SHP-1 compared with parent Huh7 cells will serve a critical
control to help figure out the importance of RFX-1/SHP-1/STAT3
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Furthermore, studies on clinical relevance of RFX-1/SHP-1/STAT3with
sorafenib resistance using primary malignant cells or biopsy samples from
patients will strengthen our current findings. More studies are needed to
further address this point.
In summary, our data provide strong evidence that RFX-1/SHP-1
activation is the driving force determining the therapeutic effect of
sorafenib onHCC cells.We further confirmed that activation of RFX-1
and SHP-1 by SC-2001 overcomes drug resistance to sorafenib inHCC
thus pointing to a possible new sorafenib combinational therapy for
HCC and the need for further clinical investigation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.06.005.
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